Tuberc Respir Dis Search


Tuberc Respir Dis > Volume 52(4); 2002 > Article
Tuberculosis and Respiratory Diseases 2002;52(4):309-316.
DOI:    Published online April 1, 2002.
Clinical Efficacy of Combination Chemotherapy with Ifosfamide Cisplatin, and Etoposide(ICE) in Advanced Non-Small Cell Lung Cancer.
Gu Lee, , Byung Duk Kim, , Hee Jung Kang, , Sang Won Lee, , Hyun A Oh, , Sung Hwa Bae, , Jae Lyun Lee, , Kyung Hee Lee, , Myung Soo Hyun, , Kyeong Cheol Shin, , Jin Hong Jung, , Kwan Ho Lee, , Hun Mo Ryu,
1Department of Internal Medicine, College of Medicine, Yeungnam University, Korea.
2Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Daegu, Korea.
To evaluate the efficacy and toxicity of combination chemotherapy using ifosfamide, cisplatin, and etoposide in patients with advanced non-small cell lung cancer(NSCLC). MATERIALS AND METHODS: Thirty-three patients with inoperable NSCLC(stage III b+IV) who had measurable diseases, and had not been treated with chemotherapeutic drugs, were enrolled in this study(from March 1995 to December 1996). The patients received ifosfamide(1500mg/m2/day, a full drop with Mesna on days 1-5), Cisplatin (80mg/m2/day infusion with a hydration on day 2), and Etoposide (100mg/m2/day infusion for 2 hours on days 1-3). The treatment was repeated every 4 weeks. RESULTS: Ten patients showed a partial responses (30.3%). The overall survival time of the responders was longer than that of the non-responders (median 55 vs 22 weeks, p=0.01). The toxicities of this treatment were tolerable. Grade 3 or 4 leukopenia was observed in 21%. There was 1 death related to febrile neutropenia. The non-hematologic toxicity was mild. The relative dose intensity given to the patients was 0.86 ifosfamide, 0.87 cisplatin, and 0.89 etoposide, showing an average dose intensity of 0.87. CONCLUSIONS: A combination regimen of ifosfamide, cisplatin, and etoposide is effective and tolerable for treating advanced non-small cell lung cancer.
Key Words: Ifosfamide, Cisplatin, Etoposide, g Non-small-cell lung cancer, Chemotherapy

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2020 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2community

Close layer
prev next